Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
430 patients that underwent pancreatectomy for resectable and borderline resectable pancreatic cancer were retrospectively reviewed.
I · Intervention 중재 / 시술
pancreatectomy for resectable and borderline resectable pancreatic cancer were retrospectively reviewed
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Tumor location (body or tail), tumor size ≥30 mm, and radiographic other-organ invasions were risk factors for positive cytology in pancreatic cancer. This scoring system might be a useful indicator to perform staging laparoscopy to diagnose positive cytology.
[BACKGROUND] The aim of this study was to evaluate factors to predict positive peritoneal cytology, whcih would determine the indication for staging laparoscopy in pancreatic cancer.
- p-value p = .004
- p-value p = .015
- 95% CI 1.21-5.85
APA
Yoshimura T, Shimizu A, et al. (2024). Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer.. Journal of hepato-biliary-pancreatic sciences, 31(7), 492-502. https://doi.org/10.1002/jhbp.1436
MLA
Yoshimura T, et al.. "Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer.." Journal of hepato-biliary-pancreatic sciences, vol. 31, no. 7, 2024, pp. 492-502.
PMID
38736090
Abstract
[BACKGROUND] The aim of this study was to evaluate factors to predict positive peritoneal cytology, whcih would determine the indication for staging laparoscopy in pancreatic cancer.
[METHODS] A total of 430 patients that underwent pancreatectomy for resectable and borderline resectable pancreatic cancer were retrospectively reviewed.
[RESULTS] Among 430 patients, 36 had positive cytology (8.4%). Median survival time in negative cytology was 24.7 months, compared with 15.1 months in positive cytology (p = .004). Factors to predict positive cytology in pancreatic cancer according to multivariate analysis were tumor location (body, tail; OR 2.66; 95% CI: 1.21-5.85; p = .015), tumor size ≥30 mm (OR 2.95; 95% CI: 1.35-6.47; p = .007) and radiographic other-organ invasion (HR 2.79; 95% CI: 1.01-7.67; p = .047). Patients were scored 0 to 3 corresponding with these factors. Rates of positive cytology increases in each score were: score 0: 2.9%, score 1: 6.7%, score 2: 18.3%, score 3: 36.8%.
[CONCLUSIONS] Tumor location (body or tail), tumor size ≥30 mm, and radiographic other-organ invasions were risk factors for positive cytology in pancreatic cancer. This scoring system might be a useful indicator to perform staging laparoscopy to diagnose positive cytology.
[METHODS] A total of 430 patients that underwent pancreatectomy for resectable and borderline resectable pancreatic cancer were retrospectively reviewed.
[RESULTS] Among 430 patients, 36 had positive cytology (8.4%). Median survival time in negative cytology was 24.7 months, compared with 15.1 months in positive cytology (p = .004). Factors to predict positive cytology in pancreatic cancer according to multivariate analysis were tumor location (body, tail; OR 2.66; 95% CI: 1.21-5.85; p = .015), tumor size ≥30 mm (OR 2.95; 95% CI: 1.35-6.47; p = .007) and radiographic other-organ invasion (HR 2.79; 95% CI: 1.01-7.67; p = .047). Patients were scored 0 to 3 corresponding with these factors. Rates of positive cytology increases in each score were: score 0: 2.9%, score 1: 6.7%, score 2: 18.3%, score 3: 36.8%.
[CONCLUSIONS] Tumor location (body or tail), tumor size ≥30 mm, and radiographic other-organ invasions were risk factors for positive cytology in pancreatic cancer. This scoring system might be a useful indicator to perform staging laparoscopy to diagnose positive cytology.
MeSH Terms
Humans; Pancreatic Neoplasms; Female; Male; Retrospective Studies; Aged; Pancreatectomy; Middle Aged; Neoplasm Staging; Laparoscopy; Adult; Predictive Value of Tests; Aged, 80 and over; Prognosis; Peritoneal Neoplasms; Cytodiagnosis; Neoplasm Invasiveness; Survival Rate